Thank you for donating!

You can donate using the following services.

News

  1. 13.05.19

    26th NPUK Annual Family Conference 2019 (Registration Form)

    NPUK ANNUAL FAMILY CONFERENCE - REGISTER NOW! Don't miss out on your chance to join the NPUK Annual Family Conference, the biggest and best event in our calendar! Which this year will be held on the 20th-22nd September at Wyboston Lakes, Bedfordshire.

    Read more
  2. 09.05.19

    Mallinckrodt - VTS-270-303 (9/5/19)

    An update from Mallinckrodt Pharmaceuticals regarding their study VTS-270-303...

    Read more
  3. 07.05.19

    NPUK News: Spring 2019

    We are happy to announce that the latest edition of NPUK News (Spring 2019) is here, full to the brim with everything our community needs - there's fundraising stories, events news, updates from staff and community members...and so much more!

    Read more
  4. 15.03.19

    CTD Holdings Announces Plan to Launch Clinical Trial of Trappsol® Cyclo™ in Alzheimer’s Disease

    ALACHUA, FL – (Globe Newswire) – March 14, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has initiated planning for a Phase I clinical trial for treatment of Alzheimer’s Disease. The trial will use Trappsol® Cyclo™, the company’s proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously.

    Read more
  5. 11.03.19

    IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC)

    IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC): OXFORD, UK, March 11, 2019-- IntraBio Inc., a late-stage biopharmaceutical company, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved its Clinical Trial Authorisation (CTA) Application for Clinical Trial IB1001-201 with its lead compound (IB1001) for the treatment of Niemann-Pick disease Type C (NPC).

    Read more